Elite Health Wesley Chapel is transforming the way men access testosterone replacement therapy across the Tampa Bay region, offering a physician-supervised model that stands in direct contrast to the ...

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction ...

The expansion will allow "thousands" more to access "life-saving cancer treatment closer to home", Health Minister Simeon Brown says.

PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S.

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and ...